Search

Displaying results 1001 - 1010 of 10000 in total
  1. Drug

    TGAAC94

    go.drugbank.com/drugs/DB06175
    Investigational

    tgAAC94 is a recombinant adeno-associated virus serotype 2 (AAV2) vector containing the cDNA for a human tumor necrosis factor receptor (TNFR)-immunoglobulin (IgG1) Fc fusion (TNFR:Fc) gene. … The Health Recombinant DNA Advisory Committee (RAC) concluded that a possible role of the gene transfer in this clinical course could not definitively be excluded due to the lack of data. [A264038]

  2. Drug

    EMD-1201081

    go.drugbank.com/drugs/DB06181
    Investigational

    Categories: Toll-Like Receptor 9, agonists
  3. Drug

    AEG35156

    go.drugbank.com/drugs/DB06184
    Investigational

    AEG35156 selectively blocks the cellular expression of X-linked inhibitor of apoptosis protein (XIAP), a pivotal inhibitor of apoptosis that is overexpressed in many tumors. … A second-generation synthetic antisense oligonucleotide with potential antineoplastic activity.

  4. Drug

    Forodesine

    go.drugbank.com/drugs/DB06185
    Investigational

    leukemia and cutaneous T-cell lymphoma. … Forodesine is a highly potent, orally active, rationally designed PNP inhibitor that has shown activity in preclinical studies with malignant cells and clinical utility against T-cell acute lymphoblastic

    Categories: Heterocyclic Compounds, 1-Ring, Heterocyclic Compounds, 2-RingSynonyms: 1,4-Dideoxy-4-aza-1-(S)-(9-deazahypoxanthin-9-yl)-D-ribitol, (1S)-1,4-dideoxy-4-imino-(9-deazahypoxanthin-9-yl)-D-ribitol
  5. Drug

    Ipilimumab

    go.drugbank.com/drugs/DB06186
    ApprovedInvestigational

    Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). … [L12126] Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes.[A35065,A35080,L12126] Ipilimumab was developed by Bristol-Myers Squibb and Medarex.

    Categories: Immunoglobulin G, CTLA-4-directed Blocking AntibodyProducts: YERVOY®5 MG /ML SOLUCION INYECTABLE PARA INFUSION INTRAVENOSA, YERVOY 5 mg/ml concentrate for solution for infusion
  6. Drug

    Ispinesib

    go.drugbank.com/drugs/DB06188
    Investigational

    Categories: Heterocyclic Compounds, 2-Ring
  7. Drug

    Seliciclib

    go.drugbank.com/drugs/DB06195
    Investigational

    R-roscovitine (Seliciclib or CYC202) is a cyclin-dependent kinase (CDK) inhibitor that preferentially inhibits multiple enzyme targets including CDK2, CDK7 and CDK9, which alter the growth phase of treated

    Categories: Heterocyclic Compounds, 2-RingSynonyms: 2-(R)-(1-ethyl-2-hydroxyethylamino)-6-benzylamino-9-isopropylpurine, R-roscovitine
  8. Drug

    Atrasentan

    go.drugbank.com/drugs/DB06199
    ApprovedInvestigational

    Atrasentan is a novel, selective endothelin A receptor antagonist (SERA). … [L52855] In April 2025, atrasentan was granted accelerated approval by the FDA for the reduction of proteinuria in patients with primary IgA nephropathy, becoming the first endothelin A receptor antagonist

    Categories: Cytochrome P-450 CYP2B6 Inducers, P-glycoprotein inhibitors
  9. Drug

    Tedisamil

    go.drugbank.com/drugs/DB06200
    Experimental

    Tedisamil (planned trade name Pulzium) is an investigational drug for atrial fibrillation and atrial flutter. It is currently being developed by Solvay and is currently under regulatory review by the United States Food and Drug Administr...

    Categories: Compounds used in a research, industrial, or household setting
  10. Drug

    Lasofoxifene

    go.drugbank.com/drugs/DB06202
    ApprovedInvestigationalWithdrawn

    It gained approval by European Commission in March 2009. … Later Fablyn was developed as a result of a research collaboration between Pfizer and Ligand Pharmaceuticals with a newly submitted New Drug Application in 2008.

    Categories: Heterocyclic Compounds, 1-RingSynonyms: (-)-cis-5,6,7,8-Tetrahydro-6-phenyl-5-(p-(2-(1-pyrrolidinyl)ethoxy)phenyl)-2-naphthol